Pfizer: Lymphoma trials
The registry lists 40 Lymphoma studies with Pfizer as lead sponsor. 0 are open to participants now and 18 have results posted.
Phase 1 20Phase 2 15Phase 3 5No phase 5(a study in two phases counts in both)
Studies
Open to participants first, then studies with results posted, then the rest; newest registration first within each.
- RITUXIMAB BS Intravenous Infusion 100mg・500mg [Pfizer] Post-marketing Database StudyCompletedNCT06790420Results posted
- Effects of Maplirpacept (PF-07901801),Tafasitamab, and Lenalidomide in People With Relapsed or Refractory Diffuse Large B-cell LymphomaTerminatedNCT05626322Phase 1/2Results posted
- Denintuzumab Mafodotin (SGN-CD19A) Combined With RCHOP or RCHP Versus RCHOP Alone in Diffuse Large B-Cell Lymphoma or Follicular LymphomaTerminatedNCT02855359Phase 2Results posted
- A Trial of PF-07901800 (TTI-621) for Patients With Hematologic Malignancies and Selected Solid TumorsTerminatedNCT02663518Phase 1Results posted
- Treatment Study of Denintuzumab Mafodotin (SGN-CD19A) Plus RICE Versus RICE Alone for Diffuse Large B-Cell LymphomaTerminatedNCT02592876Phase 2Results posted
- Study of Brentuximab Vedotin Combined With Bendamustine in Patients With Hodgkin LymphomaCompletedNCT01874054Phase 1/2Results posted
- ECHELON-2: A Comparison of Brentuximab Vedotin and CHP With Standard-of-care CHOP in the Treatment of Patients With CD30-positive Mature T-cell LymphomasCompletedNCT01777152Phase 3Results posted
- A Study of Brentuximab Vedotin With Hodgkin Lymphoma (HL) and CD30-expressing Peripheral T-cell Lymphoma (PTCL)CompletedNCT01716806Phase 2Results posted
- A Study of Brentuximab Vedotin in Relapsed or Refractory Non-Hodgkin LymphomaCompletedNCT01421667Phase 2Results posted
- A Study Of Inotuzumab Ozogamicin Plus Rituximab For Relapsed/Refractory Aggressive Non-Hodgkin Lymphoma Patients Who Are Not Candidates For Intensive High-Dose ChemotherapyTerminatedNCT01232556Phase 3Results posted
- Studying An Investigational Drug Crizotinib (PF-02341066) In Non Non-Small Cell Lung Cancer Tumors That Are Positive For Anaplastic Lymphoma Kinase (ALK)TerminatedNCT01121588Phase 1Results posted
- A Phase 3 Study of Brentuximab Vedotin (SGN-35) in Patients at High Risk of Residual Hodgkin Lymphoma Following Stem Cell Transplant (The AETHERA Trial)CompletedNCT01100502Phase 3Results posted
- Study Evaluating Inotuzumab Ozogamicin (CMC-544) In Indolent Non-Hodgkins LymphomaCompletedNCT00868608Phase 2Results posted
- A Phase 2 Open Label Trial of Brentuximab Vedotin (SGN-35) for Systemic Anaplastic Large Cell LymphomaCompletedNCT00866047Phase 2Results posted
- A Pivotal Open-Label Trial of Brentuximab Vedotin for Hodgkin LymphomaCompletedNCT00848926Phase 2Results posted
- Study Evaluating Inotuzumab Ozogamicin [CMC-544] Administered In Combination With Rituximab In Subjects With Non-Hodgkin's Lymphoma (NHL)CompletedNCT00299494Phase 1/2Results posted
- Study Evaluating Temsirolimus (CCI-779) In Mantle Cell Lymphoma (MCL)CompletedNCT00117598Phase 3Results posted
- Study Evaluating CMC-544 In B-Cell Non-Hodgkin's LymphomaCompletedNCT00073749Phase 1Results posted
- A Study to Learn About the Effects of Two Study Medicines (Maplirpacept [PF-07901801] And Glofitamab) When Given Together In People With Relapsed Or Refractory Diffuse Large B Cell Lymphoma.TerminatedNCT05896163Phase 1/2
- A Study to Learn About the Study Medicine (Called Maplirpacept (PF-07901801)) in Japanese With Hematologic MalignanciesCompletedNCT05567887Phase 1
- A Clinical Trial to Learn About the Study Medicine Called Maplirpacept (PF-07901801), Alone and When Used in Combination With Other Medicines to Treat Participants With Advanced Hematological Malignancies, Including Lymphoma, Leukemia and Multiple MyelomaTerminatedNCT03530683Phase 1
- Safety Study of SEA-CD40 in Cancer PatientsTerminatedNCT02376699Phase 1
- Epoetin Alfa Biosimilar in the Management of Chemotherapy-Induced Symptomatic Anemia in Haematology and OncologyCompletedNCT02140736
- Biosimilar Retacrit™ (Epoetin Zeta) in the Treatment of Chemotherapy-Induced Symptomatic Anaemia in Haematology and OncologyCompletedNCT01626547
- A Phase 1 Study of Brentuximab Vedotin Given Sequentially and Combined With Multi-Agent Chemotherapy for CD30-Positive Mature T-Cell and NK-Cell NeoplasmsCompletedNCT01309789Phase 1
- A Treatment-Option Protocol to Provide Brentuximab Vedotin to Eligible Patients Completing Studies SGN35-005 or C25001No longer availableNCT01196208
- A Phase 1 Study of Brentuximab Vedotin Combined With Multi-Agent Chemotherapy for Hodgkin LymphomaCompletedNCT01060904Phase 1
- Clinical Pharmacology Study of Brentuximab Vedotin (SGN-35)CompletedNCT01026415Phase 1
- Cardiac Safety Study of Brentuximab Vedotin (SGN-35)CompletedNCT01026233Phase 1
- Trial to Define the Safety and Tolerability of SGN-40, Rituximab, and Gemcitabine in Patients With DLBCLCompletedNCT00655837Phase 1
- A Phase I Dose Escalation Study of SGN-35 Alone and in Combination With Gemcitabine for CD30-Positive MalignanciesTerminatedNCT00649584Phase 1
- A Randomized Phase IIb Placebo-Controlled Study of R-ICE Chemotherapy With and Without SGN-40 for Patients With DLBCLTerminatedNCT00529503Phase 2
- Phase I Trial of PX-478CompletedNCT00522652Phase 1
- Study of SGN-40 in Patients With Relapsed Diffuse Large B-Cell LymphomaCompletedNCT00435916Phase 2
- Phase I Open-Label Dose Finding Study of SGN-35 for CD30 Positive Hematologic MalignanciesCompletedNCT00430846Phase 1
- Study Comparing Piperacillin-tazobactam Versus Piperacillin-tazobactam Plus Glycopeptide in Neutropenic PatientsCompletedNCT00195533
- A Safety Study of SGN-40 in Patients With Non-Hodgkin's LymphomaCompletedNCT00103779Phase 1
- Study of SGN-30 (Antibody) in Patients With Refractory or Recurrent Anaplastic Large Cell LymphomaCompletedNCT00079755Phase 2
- CPG 7909 in Patients With Cutaneous T-Cell LymphomaCompletedNCT00043420Phase 1/2
- Safety and Efficacy of (PN-152,243)/PN-196,444 in the Prevention of ThrombocytopeniaCompletedNCT00037791Phase 3